Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are promising drugs for the treatment of HIV when used in combination with other anti-HIV drugs such as nucleoside reverse transcriptase (RT) inhibitors and protease inhibitors. The first generation of NNRTIs have, however, suffered from the rapid development of resistance. This review discusses the properties of the FDA-approved NNRTI drugs and focuses on the recent efforts being made to produce second generation inhibitors that circumvent this resistance problem.
Antiviral Chemistry and Chemotherapy – SAGE
Published: Jun 24, 2016
Keywords: HIV-1,non-nucleoside reverse transcriptase inhibitors,HEPT,nevirapine,delavirdine,efavirenz,trovirdine